Skip to main content

Market Overview

XenoPort (XNPT) Shares Fall 65% After FDA Rejection


Shares of XenoPort, Inc. (Nasdaq: XNPT) crashed today after the pharmaceutical company received word from the FDA that it would not approve the company's development stage drug called Horizant, which XenoPort developed with partner GlaxoSmithKline Plc (NYSE: GSK).

The FDA said that pancreatic tumor cells were found in lab rats that the drug was being tested on.

Shares of XenoPort crashed and the company received the following downgrades:

Argus downgraded XenoPort from Buy to Sell.

Citigroup downgraded XenoPort from Hold to Sell, with a price target lowered from $20 to $10.

Benchmark downgraded XenoPort from Buy to Hold and lowered the price target from $26 to$7.

Ladenburg Thalmann downgraded XenoPort from Buy to Sell.

Hapoalim downgraded XenoPort from Outperform to Underperform with a price target of $10.


Related Articles (XNPT + GSK)

View Comments and Join the Discussion!

Posted-In: ArgusNews Downgrades Price Target FDA Markets Analyst Ratings Movers

Latest Ratings

NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at